Laia Vilà
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Laia Vilà has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Enric Carcereny
Catalan Institute of Oncology – Badalona, B-ARGO Group, Barcelona, Spain
1 shared publication - Jordi Remon
Hospital Vall d'Hebron, Barcelona, Spain
1 shared publication - Laia Capdevila
Hospital de Sant Pau i Santa Tecla, Tarragona, Tarragona, Spain
1 shared publication - Maria de Los Llanos Gil
Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Universitat Autónoma de Barcelona, Department of Medicine, Badalona, Barcelona Spain
1 shared publication - Rafael Rosell
Instituto Oncológico Dr. Rosell (IOR), Dexeus University Hospital, Barcelona, Spain
1 shared publication - Sara Cros
Hospital de Granollers, Barcelona, Spain
1 shared publication
Latest Publications
- Open Access
- 24 February 2015
- Published by Springer Nature in Translational Respiratory Medicine
- Vol. 3 (1) , 1
The epidermal growth factor receptor (EGRF) in lung cancer
In the last decade, important advances have been made in understanding of cancer biology, particularly non-small-cell lung cancer (NSCLC) with the discovery of oncogenic drivers of the disease. The epidermal growth factor receptor (EGFR) gene and its pathways was the first oncogenic driver discovered to be mutated and treatable in lung cancer. Treatment with EGFR tyrosine kinase inhibitors (TKIs) is the standard of care for molecularly selected EGFR-mutant patients, while its role in unselected lung cancer patients is nowadays controversial. This review will provide an overview of the EGFR pathway and options for its treatment of lung cancer.
- 24 February 2015
- Published by Springer Nature in Translational Respiratory Medicine
- Vol. 3 (1) , 1
Open AccessThe epidermal growth factor receptor (EGRF) in lung cancer
In the last decade, important advances have been made in understanding of cancer biology, particularly non-small-cell lung cancer (NSCLC) with the discovery of oncogenic drivers of the disease. The epidermal growth factor receptor (EGFR) gene and its pathways was the first oncogenic driver discovered to be mutated and treatable in lung cancer. Treatment with EGFR tyrosine kinase inhibitors (TKIs) is the standard of care for molecularly selected EGFR-mutant patients, while its role in unselected lung cancer patients is nowadays controversial. This review will provide an overview of the EGFR pathway and options for its treatment of lung cancer.